Search Results for "HIV"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for HIV. Results 81 to 90 of 181 total matches.

CYP3A and Drug Interactions

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 2005  (Issue 1212)
*), vinblastine (Velban*), vincristine (Oncovin*) HIV protease inhibitors: amprenavir (Agenerase), atazanavir ...
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.
Med Lett Drugs Ther. 2005 Jul 4;47(1212):54-5 |  Show IntroductionHide Introduction

Secnidazole (Solosec) for Bacterial Vaginosis

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018  (Issue 1543)
with an increased risk of HIV and other sexually transmitted infections (STIs), upper genital tract infections ...
The FDA has approved secnidazole oral granules (Solosec – Symbiomix/Lupin) for single-dose treatment of bacterial vaginosis (BV) in adult women.
Med Lett Drugs Ther. 2018 Mar 26;60(1543):52-3 |  Show IntroductionHide Introduction

Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
most patients with HIV infection, oral valacyclovir or famciclovir can be used. ACYCLOVIR — Acyclovir ...
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Sep 24;60(1556):153-7 |  Show IntroductionHide Introduction

Granulocyte Colony-Stimulating Factors

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 1991  (Issue 847)
and decrease HIV proliferation and to increase the anti-HIV activity of zidovudine (C-F Perno et al, J Exp Med ...
The US Food and Drug Administration recently approved the marketing of G-CSF (recombinant human granulocyte colony-stimulating factor, generic name filgrastim, Neupogen - Amgen) and GM-CSF (recombinant human granulocyte-macrophage colony-stimulating factor, generic name sargramostim, Leukine - Immunex, Prokine - Hoechst-Roussel). G-CSF is approved for use after cancer chemotherapy in patients with non-myeloid malignancies to decrease the incidence of infection. GM-CSF is approved for acceleration of myeloid recovery after autologous bone marrow transplantation in non-Hodgkin's lymphoma,...
Med Lett Drugs Ther. 1991 Jun 28;33(847):61-3 |  Show IntroductionHide Introduction

In Brief: A Shorter Treatment Regimen for Tuberculosis (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
- or three-times-weekly dosing can be used as an alternative in patients who are HIV-negative and do ...
In a clinical trial conducted by the CDC's Tuberculosis Trials Consortium in collaboration with the NIH-funded AIDS Clinical Trials Group, a new 4-month regimen for treatment of drug-susceptible pulmonary tuberculosis was found to be noninferior to 6 months of standard treatment.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):e3 |  Show IntroductionHide Introduction

Some Drugs for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020  (Issue 1595)
, HIV protease inhibitors, ribavirin, interferon, chloroquine/hydroxychloroquine, and azithromycin.11 ...
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50 |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
, 21-30 days, and 12 months is also FDA-approved. 18. HIV infection, functional or anatomic asplenia ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

The Female Condom

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993  (Issue 912)
— Virus penetration tests for HIV and cytomegalovirus detected no leakage of virus through the Reality ...
A condom for women (Reality - Wisconsin Pharmacal) to prevent pregnancy and sexually transmitted diseases, including AIDS, has been approved for marketing by the US Food and Drug Administration (FDA). Already available in many family planning clinics, it will be available in pharmacies in a few months.
Med Lett Drugs Ther. 1993 Dec 24;35(912):123-4 |  Show IntroductionHide Introduction

Alglucerase For Gaucher's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 1991  (Issue 851)
procedures used in the manufacture of alglucerase inactivate many viruses, including HIV, and may inactivate ...
(Ceredase - Genzyme) a modified form of the glycoprotein enzyme glucocerebrosidase prepared from human placenta, was recently approved by the US Food and Drug Administration as an 'orphan drug' for treatment of patients with the non-neurologic form of Gaucher's disease (Type 1).
Med Lett Drugs Ther. 1991 Aug 23;33(851):82 |  Show IntroductionHide Introduction

Dehydroepiandrosterone (DHEA)

   
The Medical Letter on Drugs and Therapeutics • Oct 11, 1996  (Issue 985)
, Ann NY Acad Sci, 774:259, 1995). CLINICAL USE — An uncontrolled trial in HIV-infected patients ...
Dehydroepiandrosterone (DHEA) is an adrenal androgen now being marketed as a "food supplement"in health food stores. DHEA is not approved for any indication by the US Food and Drug Administration (FDA).
Med Lett Drugs Ther. 1996 Oct 11;38(985):91-2 |  Show IntroductionHide Introduction